California Neurology Society (CNS) Advocacy

You are formally invited to join the California Neurology Society for our cornerstone event: the 2026 Legislative Advocacy Day in Sacramento on Monday, April 13th.

Last year, we walked the halls of the State Capitol as a unified community. Through purposeful meetings and shared stories, we turned the concerns of neurologists and patients into a legislative priority. That direct advocacy made a measurable difference. This year, we return with even greater focus and momentum.

This is a professionally organized day designed for maximum impact. We will equip you completely. The event begins with a comprehensive morning briefing, where you will receive training on our key legislative priorities, concise messaging, and effective meeting protocols. Following the briefing, you will join a small, pre-assigned team blending neurologists and advocates for a series of scheduled meetings with legislative offices throughout the Capitol.

To express your interest in participating and for more details, please contact us directly at LEDGE@caneurologysociety.org.

The California Neurology Society is supporting a statewide prospective registry to advance understanding of Multiple Sclerosis (MS) and related autoimmune neurological diseases. Led by Principal Investigator Dr. Johanna Rosenthal, this collaborative effort brings together neurologists from Arrowhead Regional Medical Center, Riverside Community Hospital, and across California.

This registry collects de‑identified laboratory and clinical data—including immunoglobulin subclasses, lymphocyte populations, and flow cytometry results—to evaluate how modern Disease Modifying Therapies (DMTs) affect the immune system.

Participating neurologists submit data from consenting adult patients, with testing performed at standardized intervals before and after treatment.

By freezing and analyzing data quarterly, the registry aims to provide clinicians with meaningful insights into treatment response, support evidence‑based use of high‑cost therapies, and create a long‑term resource for research. The project includes an initial one‑year cohort of 100 patients, with potential for expansion based on findings.